Modality
Cell Therapy
MOA
CD47i
Target
PARP
Pathway
Hedgehog
NarcolepsyAtopic Derm
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
~Sep 2018
→ ~Dec 2019
Phase 2
Mar 2020
→ Jun 2025
Phase 2Current
NCT04796838
312 pts·Narcolepsy
2020-03→2025-06·Completed
312 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0210mo agoPh3 Readout· Narcolepsy
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2/3
Complet…
Catalysts
Ph3 Readout
2025-06-02 · 10mo ago
Narcolepsy
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04796838 | Phase 2/3 | Narcolepsy | Completed | 312 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |